Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysis.

ABSTRACT:

Introduction

Soft tissue sarcomas (STS) are a rare and diverse group of mesodermal-origin cancers with limited systemic treatment options in advanced-stage disease. Recent evidence suggests that combination therapies involving tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptor (VEGFR) and immune checkpoint inhibitors (ICIs) may enhance clinical outcomes.

Methods

We conducted a systematic review and meta-analysis. Databases were searched for prospective clinical trials evaluating ICIs and VEGFR-TKIs combination therapy in adults with advanced STS. Primary outcomes were objective response rating (ORR), overall survival (OS), and progression-free survival (PFS). A subgroup analysis was performed for alveolar soft part sarcoma (ASPS). We

SUBMITTER: Dias E Silva D 

PROVIDER: S-EPMC12578506 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature